NKGen Biotech ( NASDAQ:NKGN ), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (NK) cell therapeutics, has announced that its Safety Review Committee has cleared the company's cryopreserved autologous, expanded, and enhanced SNK01 to progress into Phase 2...
It came to my attention at around 1.54 with an abnormal volume. Currently sitting at around 1.65 with an abnormal price and volume action. Potential to go up further.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation...